News for DARA Biosciences Inc - Google Finance

DARA BioSciences Inc grants T3D Therapeutics its exclusive worldwide rights to ...

Wed, 19 Jun 2013 08:57:54 GMT

DARA BioSciences Inc grants T3D Therapeutics its exclusive worldwide rights to ...
MENAFN.COM - 20 hours ago

DARA BioSciences Inc grants T3D Therapeutics its exclusive worldwide rights to DB959 for treating diabetes and dyslipidemia.

DARA BioSciences Grants T3D Therapeutics Exclusive Worldwide Rights to ...

Tue, 18 Jun 2013 12:02:10 GMT

DARA BioSciences Grants T3D Therapeutics Exclusive Worldwide Rights to ...
Marketwire (press release) - Jun 18, 2013

RALEIGH, NC--(Marketwired - June 18, 2013) - DARA BioSciences, Inc. ( NASDAQ : DARA), a specialty pharmaceutical company focused on oncology supportive care products, announced today that it has granted T3D Therapeutics, Inc. the exclusive ...

Hyperdynamics Corporation (NYSE:HDY) shares up by 2.30%, DARA ...

Wed, 29 May 2013 08:16:57 GMT

Hyperdynamics Corporation (NYSE:HDY) shares up by 2.30%, DARA ...
GSPInsider - May 29, 2013

Hartford, CT 05/29/2013 (GDPInsider) - Hyperdynamics Corporation (NYSE:HDY) shares closed at $0.520 up by 2.30% (+$0.012) compared to previous day's close of about $0.51.

Vermillion Inc. (NASDAQ:VRML) down by 6.45%, DARA Biosciences Inc ...

Wed, 12 Jun 2013 18:55:43 GMT

Vermillion Inc. (NASDAQ:VRML) down by 6.45%, DARA Biosciences Inc ...
NIS - Jun 12, 2013

New York, NY - (NISMAGAZINE) - 06/12/2013- Vermillion Inc. (NASDAQ:VRML) went down by 6.45% to trade at $2.90, with a volume of 264K shares.

DARA Biosciences Enrolls Leading Oncology Centers in Breast Cancer Patient ...

Mon, 03 Jun 2013 11:32:51 GMT

DARA Biosciences Enrolls Leading Oncology Centers in Breast Cancer Patient ...
MarketWatch (press release) - Jun 3, 2013

RALEIGH, NC AND CHICAGO, IL, Jun 03, 2013 (Marketwired via COMTEX) -- DARA BioSciences, Inc. (NASDAQ:DARA) , a specialty pharmaceutical company focused on oncology supportive care products, announced today that the Company has enrolled ...

DARA Biosciences Inc Announces Submission Of Krn5500 To FDA For Orphan Designation

Thu, 29 Nov 2012 13:00:00 GMT

DARA Biosciences Inc Announces Submission Of Krn5500 To FDA For Orphan Designation
Reuters Key Development - Nov 29, 2012

Helsinn Group Grants To DARA Biosciences Inc Exclusive U.S. Commercial Rights To Gelclair

Thu, 13 Sep 2012 12:30:00 GMT

Helsinn Group Grants To DARA Biosciences Inc Exclusive U.S. Commercial Rights To Gelclair
Reuters Key Development - Sep 13, 2012

DARA Biosciences Inc Announces Launch Of Bionect For Treatment Of Skin Irritation And Burns Associated With Radiation Therapy For Cancer

Wed, 06 Jun 2012 12:45:00 GMT

DARA Biosciences Inc Announces Launch Of Bionect For Treatment Of Skin Irritation And Burns Associated With Radiation Therapy For Cancer
Reuters Key Development - Jun 6, 2012

DARA Biosciences Inc Announces Appointment Of President

Tue, 29 May 2012 12:45:00 GMT

DARA Biosciences Inc Announces Appointment Of President
Reuters Key Development - May 29, 2012

DARA Biosciences Inc Announces New Analysis of Patient Self-Reported Diary Results In A Phase 2a Clinical Trial Of KRN5500 In Patients With Cancer And Neuropathic Pain

Wed, 09 May 2012 12:45:00 GMT

DARA Biosciences Inc Announces New Analysis of Patient Self-Reported Diary Results In A Phase 2a Clinical Trial Of KRN5500 In Patients With Cancer And Neuropathic Pain
Reuters Key Development - May 9, 2012